

30 September 2026

Sydney, Australia

Nyrada US Patent for Xolatryp® Granted

Nyrada Inc. (ASX:NYR), a clinical-stage biotechnology company focused on developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions, is pleased to announce its composition of matter patent for Xolatryp® has been granted.

[Nyrada's granted patent](#) will provide intellectual property protection within the United States over Xolatryp's chemical structure, with a 20-year term from the September 2024 filing date.

A composition of matter patent protects against the unauthorised manufacture, use, sale, or import of Xolatryp without Nyrada's approval. The US application forms part of a broader global patent portfolio to be filed by the Company across key jurisdictions including Australia, Europe, and Japan.

-ENDS-



About Xolatryp®

Xolatryp is a small-molecule inhibitor of TRPC3/6/7 channels designed to limit excessive Ca^{2+} entry related to multiple disease pathologies.

[A Phase I clinical trial to assess the safety, tolerability, and pharmacokinetics has been successfully completed](#) and a [Phase IIa clinical trial](#) has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing percutaneous coronary intervention (PCI).

Key Links:

Cardioprotection

- PROTECT-MI website - <https://www.protect-mi.com>
- PROTECT-MI NIH Entry - <https://bit.ly/4cB2fF9>
- Phase IIa factsheet - <https://bit.ly/4bcDIKj>
- Preclinical cardioprotection study 1a - <https://bit.ly/4sigwMZ>
- Preclinical cardioprotection study 1b - <https://bit.ly/4rmOsXn>
- Preclinical cardioprotection study 2 - <https://bit.ly/40jHpUg>

Oncology

- Preclinical cardiomyopathy study - <https://bit.ly/4yR9BgD>
- Preclinical cardiomyopathy pilot study - <https://bit.ly/4xJH3Fj>
- Preclinical anti-tumour study - <https://bit.ly/49rWOa0>

Neuroprotection

- Preclinical traumatic brain injury study - <https://bit.ly/40fhrRT>
- Preclinical stroke study - <https://bit.ly/4sygHmH>

Foundations

- Phase I results - <https://bit.ly/3Nt0GzH>
- Preclinical mitochondria stabilisation study - <https://bit.ly/4yiZUHa>
- GLP study results - <https://bit.ly/4d8VYkX>
- CSANZ Conference Poster - <https://bit.ly/4A9ROmf>

Corporate

- Latest presentation slides - <https://bit.ly/46FM9Xq>



About Nyrada Inc.

Nyrada Inc. is a clinical stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp®, has shown efficacy in preclinical cardioprotection, neuroprotection, and oncology models and has completed a first-in-human Phase I clinical trial. A Phase IIa clinical trial has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing PCI. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

Authorised by Mr. James Bonnar, CEO and Managing Director on behalf of the Board.

Investor & Media Enquiries:

Dimitri Burshtein

T: 0491 789 391

E: info@nyrada.com

Company Secretary:

David Franks

T: 02 8072 1400

E: David.Franks@automicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.